On May 23, the U.S. Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) for the treatment of unresectable or metastatic solid tumors with the biomarker microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Read more
© 2021 HealthCom Media All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder.